SIU Academy is a digital learning resource for urologists
Enter the portal

 

 

Thank you for all who joined us in Berlin, or online via SIU Academy to catch up on the tremendous advancements being made in diagnosis and treatment with the recent FDA approval of a targeted therapy for metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations, two combination immunotherapy-targeted therapies as first-line treatment for advanced RCC, as well as advances in diagnostics and immunotherapy research for prostate cancer.

Watch SIU Academy in January 2020 for upcoming webcasts from this highly anticipated event and immerse yourself in the evolving landscape of urological cancer care.